Dupont Capital Announces Proposed Qualifying Transaction

MONTREAL, QUEBEC--Dupont Capital Inc. ("Dupont") (TSX Venture:
DPN.P) announces today that it has, on March 12, 2004, signed an
arm's length Memorandum of Understanding (the "Agreement") with
Advitech Solutions Inc. ("Advitech") for the amalgamation of
their respective companies (the "Amalgamation"). It is
anticipated that the company resulting from the Amalgamation will
be known as Advitech Inc.


- Advitech is a nutraceutical company specializing in the
development of new therapies, based on bioactive peptides, for
health conditions and diseases of the immune system. Advitech has
undertaken a first round of clinical trials for its newly
developed compound, XP-828L, a treatment for psoriasis. Psoriasis
is a chronic disease affecting more than 5 million people in
North America.

- The proposed Business Combination will be completed
concurrently with a financing for a minimum of $3.0 million.
Desjardins Securities has agreed to act as agent for this

About Advitech Solutions Inc.

Advitech is involved in the research, development and marketing
of nutraceutical technologies and products. Advitech is a
recognized leader in the area of bioactive peptides derived from
milk proteins. Its key focus areas are in the fields of
immunology and inflammatory processes. The company has 16
employees, with more than half of its staff engaged in research
and development activities at its facility at Universite Laval in
Quebec City.

In May 2003, Advitech Solutions signed a license agreement with
Pierre Jouan Biotechnology SA, a French biotech company. Under
this agreement, Advitech has the right to use Jouan's
patent-pending compound and process for the development of
therapeutic applications for psoriasis and other similar
auto-immune health conditions like inflammatory bowel disease
(IBD) and Crohn's disease. This agreement also gives Advitech
exclusive commercial rights to these applications for many
worldwide markets, including North America.

Using this technology, Advitech developed XP-828L, a growth
factor-based compound. In January 2004, Advitech undertook its
first round of clinical trials in collaboration with a recognized
clinical research organization in dermatology. Results from these
trials, which involve 12 patients, are expected to be available
during the 2nd quarter of 2004. Advitech's strategy is to conduct
additional clinical trials later on in 2004 to confirm the
potential of XP-828L. Anecdotal results obtained by Jouan for
patients who have used this compound for 8 weeks have shown a
significant reduction in Psoriasis symptoms, without any
noticeable side-effects.

Psoriasis is a common immune-mediated chronic skin disease that
comes in different forms and varying levels of severity. Most
researchers now conclude that it is an auto immune disorder. This
disease affects more than 4.5 million adults in the United
States, and its prevalence in other countries can reach between
2-3% of the total population. The market for psoriasis treatments
is estimated at $US 1.0 billion.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.